Subject demographics, risk group, and baseline laboratory data
| Subject | HIV-1 subtype | Geographic location | Gender | Risk group | Sampling date | VL | Clinical specimen | EIA | WB | Fiebig stagea |
| WITO4160 | B | Alabama | M | Heterosexual | 08.04.00 | 325,064 | Plasma | neg | neg | II |
| SUMA0874 | B | Alabama | M | MSM | 05.13.91 | 939,260 | Plasma | neg | neg | II |
| WEAU0575 | B | Alabama | M | MSM | 05.30.90 | 216,415 | Plasma | neg | neg | II |
| TRJO4551 | B | Alabama | M | MSM | 10.10.01 | 8,121,951 | Plasma | neg | neg | II |
| 04013226-2 | B | New York | M | MSM | 11.20.02 | 26,700,000 | Plasma | neg | neg | II |
| 04013396-0 | B | New York | M | MSM | 08.16.05 | 1,600,000 | Plasma | pos | ind | IV |
| CH40 (700010040) | B | North Carolina | M | MSM | 07.11.06 | 2,197,248 | Serum | neg | neg | II |
| CH40 (700010040) | 07.27.06 | 298,026 | Plasma | pos | pos (p31−) | V | ||||
| CH58 (700010058) | B | North Carolina | M | MSM | 08.22.06 | 92,581 | Serum | neg | neg | II |
| CH58 (700010058) | 08.31.06 | 394,649 | Plasma | pos | neg | III | ||||
| CH77 (700010077) | B | North Carolina | M | MSM | 08.25.06 | 3,565,728 | Serum | neg | neg | II |
| CH77 (700010077) | 09.08.06 | 144,145 | Plasma | pos | pos (p31−) | V | ||||
| ZM246F | C | Zambia | F | Heterosexual | 01.14.03 | 10,013,800 | Plasma | neg | neg | II |
| ZM249M | C | Zambia | M | Heterosexual | 08.05.03 | >2,000,000 | Plasma | pos | ind | IV |
| ZM247F | C | Zambia | F | Heterosexual | 10.28.03 | 10,823,500 | Plasma | neg | neg | II |
| Subject | HIV-1 subtype | Geographic location | Gender | Risk group | Sampling date | VL | Clinical specimen | EIA | WB | Fiebig stagea |
| WITO4160 | B | Alabama | M | Heterosexual | 08.04.00 | 325,064 | Plasma | neg | neg | II |
| SUMA0874 | B | Alabama | M | MSM | 05.13.91 | 939,260 | Plasma | neg | neg | II |
| WEAU0575 | B | Alabama | M | MSM | 05.30.90 | 216,415 | Plasma | neg | neg | II |
| TRJO4551 | B | Alabama | M | MSM | 10.10.01 | 8,121,951 | Plasma | neg | neg | II |
| 04013226-2 | B | New York | M | MSM | 11.20.02 | 26,700,000 | Plasma | neg | neg | II |
| 04013396-0 | B | New York | M | MSM | 08.16.05 | 1,600,000 | Plasma | pos | ind | IV |
| CH40 (700010040) | B | North Carolina | M | MSM | 07.11.06 | 2,197,248 | Serum | neg | neg | II |
| CH40 (700010040) | 07.27.06 | 298,026 | Plasma | pos | pos (p31−) | V | ||||
| CH58 (700010058) | B | North Carolina | M | MSM | 08.22.06 | 92,581 | Serum | neg | neg | II |
| CH58 (700010058) | 08.31.06 | 394,649 | Plasma | pos | neg | III | ||||
| CH77 (700010077) | B | North Carolina | M | MSM | 08.25.06 | 3,565,728 | Serum | neg | neg | II |
| CH77 (700010077) | 09.08.06 | 144,145 | Plasma | pos | pos (p31−) | V | ||||
| ZM246F | C | Zambia | F | Heterosexual | 01.14.03 | 10,013,800 | Plasma | neg | neg | II |
| ZM249M | C | Zambia | M | Heterosexual | 08.05.03 | >2,000,000 | Plasma | pos | ind | IV |
| ZM247F | C | Zambia | F | Heterosexual | 10.28.03 | 10,823,500 | Plasma | neg | neg | II |
EIA, enzyme-linked immunosorbant assay for HIV-1; ind, indeterminant; MSM, men who have sex with mena; VL, viral load (RNA molecules/ml); WB, Western blot for HIV-1.
Fiebig clinical serological staging system (17).